In addition to addressing the safety and efficacy of drug-eluting stents (DES) in general and relative to one another, randomized controlled trials and registries are now beginning to assess specific lesion subgroups for which DES are not currently approved in the US. These include in-stent restenosis, saphenous vein grafts, bifurcation lesions, left main disease, andContinueContinue reading “DES data in high-risk subgroups presented”
Category Archives: conferences
Next generation of DES discussed at Stent Revolution meeting
Several presentations focusing on the safety, efficacy, and appropriate usage of emerging drug-eluting stent technologies were highlighted at the Cardiovascular Research Foundation’s “Enter the Drug-Eluting Stent Revolution V” summit, held in mid March immediately before the annual meeting of the American College of Cardiology. Proceedings of TCT 3, 7-9 (2006). view PDF
Fluent in Science 